The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a practice-changing trial, according to experts. Medscape Medical

New research shows GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, published in the peer-reviewed journal Thyroid, the

A MOTHER has revealed that she has lost 10 and a half stone after using Mounjaro.  Becca Banks, a mum-of-one from the UK, confirmed that

A large majority of older Americans feel that health insurance – including Medicare – should cover anti-obesity medications, according to a new University of Michigan

We recently published a list of Was Jim Cramer’s Call Right on These 10 Stocks? In this article, we are going to take a look

Novo Nordisk’s diabetes pill slashes risk of cardiovascular complications by 14% after four years  CNBC Semaglutide, or Ozempic, reduces symptoms of feared diabetes’ complication, study finds  The

(Note: Thank you for supporting businesses like the one presenting a sponsored message below and working with them through the links below which benefits Gateway

A MOTHER has revealed that she lost over eight stone after using fat jabs for two years. Bridget claimed that everyone said she would regret

We came across a bullish thesis on Viemed Healthcare, Inc. (VMD) on Substack by Petty Cash. In this article, we will summarize the bulls’ thesis on VMD.

Understanding the role of the brain in hedonic eating—the act of eating for pleasure rather than for physiological need—has been a popular endeavor. Researchers at

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term

Patients with diabetes who take semaglutide are at increased risk for NAION compared with patients who do not use GLP-1 RAs to control their blood

Abstract Aims Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by β-cell damage and absolute insulin deficiency. We consider combining immune intervention and

Summary Lymphedema is an important, and often underdiagnosed complication of obesity and is likely due to acquired defects in the lymphatic vasculature. Study of diet-induced

The partnership will give customers easy access to GLP-1 class drugs and other anti-obesity medications.  

Sen. Jim Banks (R-Ind.) wants the Food and Drug Administration to look into foreign-made active pharmaceutical ingredients he says are being included online weight loss

Regaining weight after discontinuing GLP-1s is common, but ongoing coaching can help support patients to maintain their weight loss. Medscape Diabetes & Endocrinology

(MedPage Today) — CHICAGO — Coming this weekend, the American College of Cardiology (ACC) annual conference will feature research exploring new frontiers for GLP-1 drugs

Viking Therapeutics VKTX announced that it has completed enrolling study participants in the phase II VENTURE-Oral Dosing study, which is evaluating the safety and efficacy

Over the last couple of years, the pharmaceutical sector has captivated investors thanks in large part to novel medications used to treat chronic weight management

Many pharmaceutical companies and laboratories have been working for months to replicate the success of drugs such as Ozempic, Wegovy, and Zepbound. These medications are

The obesity market is driving pharma’s return on investment (ROI) upward, with the projected return rising to 5.9% overall in 2024, but only reaching 3.8%

I’ve been meaning to write about this paper, although it’s not exactly medicinal chemistry (!) But it is a really novel – and rather daring